The Washington Post | A team of researchers inside Pfizer found the company's blockbuster rheumatoid arthritis therapy Enbrel, a powerful anti-inflammatory drug, appeared to reduce the risk of Alzheimer's disease by 64%. However, Pfizer opted against further investigation and chose not to make the data public, the company confirmed.
June 5, 2019 | A team of researchers inside Pfizer found the company's blockbuster rheumatoid arthritis therapy Enbrel, a powerful anti-inflammatory drug, appeared to reduce the risk of Alzheimer's disease by 64%. However, Pfizer opted against further investigation and chose not to make the data public, the company confirmed. The Washington Post